Weight‐neutral effect of once‐daily insulin detemir in C hinese type 2 diabetes patients: Subgroup analysis of the SOLVE study 一天一次地特胰岛素对中国2型糖尿病患者体重的中性影响：SOLVE研究亚组分析

Background The present subanalysis of the Study of Once Daily Levemir ( SOLVE ) study was to evaluate the safety and efficacy of once‐daily insulin detemir as add‐on to oral antidiabetic drugs ( OAD s) in C hinese type 2 diabetes patients according to body mass index in a real‐life setting. Methods In all, 3272 eligible patients who were treated with diet, exercise, and one or more OAD were prescribed once‐daily insulin detemir by their physician according to routine clinical practice and were followed‐up for 24 weeks. The incidence of serious adverse reactions ( SADR s), including major hypoglycemia, was the primary endpoint. Subanalyses were performed on patients in the following BMI groups: normal weight ( BMI  < 25 kg/m 2 ); overweight (25 ≤  BMI  < 30 kg/m 2 ); and obese ( BMI  ≥ 30 kg/m 2 ). Results No SADRs were reported during the study. Significant improvements in glycemic levels were observed in all subgroups. For normal weight, overweight, and obese patients, the mean change in HbA1c (%/[mmol/mol]) was −1.26/−14, −1.09/−12, and −1.06/−12, respectively. The mean change in fasting plasma glucose in normal weight, overweight, and obese patients was −2.77, −2.57, and −2.71 mmol/L, respectively. Slight weight gain (0.25 kg), slight weight loss (–0.36 kg), and weight loss (–1.32 kg) were observed in the normal weight, overweight, and obese patients, respectively ( P  < 0.001). Linear regression analysis revealed a negative relationship between weight change and baseline BMI (slope = −0.16; P  < 0.001). Conclusions Once‐daily insulin detemir as add‐on to OAD s in C hinese patients with type 2 diabetes showed effective glycemic control and a low risk of hypoglycemia. Weight‐neutral effects were observed in different BMI subgroups.